Skip to main content

stock

LCTX · Lineage Cell Therapeutics, Inc.

What Lineage Cell Therapeutics, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live LCTX price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on LCTX.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
252,907,464 as of 2026-08-03 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-205.2%
Net
-246.6%

Returns

ROE
-53.0%
ROA
-30.4%

Health

Current ratio
6.6x
Debt/equity
—

Deep value

NCAV
$6.55M
NCAV per share
$0.03
Price/NCAV
Locked
NNWC
-$8.47M
NNWC per share
-$0.03
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
2026-06-30$1.07M—-$8.92M$1.48M
10-Q filed 2026-08-06
2026-03-31$1.73M—-$7.59M-$4.81M
10-Q filed 2026-05-12
2025-12-31$6.61M—-$6.55M$851,000
DEF 14A filed 2026-04-29
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$3.68M—-$3.79M-$29.78M
10-Q filed 2025-11-06
2025-06-30$2.77M—-$19.78M-$30.46M
10-Q filed 2026-08-06
2025-03-31$1.50M—-$6.50M-$4.14M
10-Q filed 2026-05-12
2024-12-31$2.87M—-$5.11M-$3.27M
DEF 14A filed 2026-04-29
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$3.78M—-$3.84M-$3.03M
10-Q filed 2025-11-06
Assets
$106.22M
Equity
$60.92M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$14.56M-$36.62M-$63.53M-$19.44M
2024-12-31$9.50M-$21.48M-$18.61M-$23.66M
2023-12-31$8.95M-$24.73M-$21.49M-$29.24M
2022-12-31$14.70M-$22.52M-$26.27M$646,000
2021-12-31$4.34M-$49.21M-$43.02M-$23.90M
2020-12-31$1.83M-$26.45M-$20.65M-$19.82M
2019-12-31$3.52M-$38.88M-$11.71M-$32.39M
2018-12-31$4.99M-$41.80M-$45.99M-$31.44M
2017-12-31$3.46M-$38.90M-$19.98M-$31.84M
2016-12-31$5.92M-$58.97M$33.57M-$44.57M

Company filings

since Wed Mar 11 · 2 offering filings in 12 months

events

  • Results

    Results
    Aug 68-K
  • Shareholder vote results, Other event

    Shareholder vote resultsOther event
    Jun 128-K
  • Results

    Results
    May 128-K
  • Other event

    Other event
    Mar 118-K
  • Results

    Results
    Mar 58-K
  • Other event

    Other event
    11/28/20258-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

No insider buys or sales filed in the last 90 days.

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named LCTX, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about LCTX.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about LCTX.

nakagai

Signals on LCTX come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the LCTX board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Lineage Cell Therapeutics, Inc. (LCTX): SEC filings, financials and insider trades · Nakagai